Tango Therapeutics Q4 GAAP EPS $(0.32) Misses $(0.28) Estimate, Sales $5.43M Miss $8.24M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics (NASDAQ:TNGX) reported Q4 GAAP EPS of $(0.32), missing the $(0.28) estimate, and sales of $5.43M, missing the $8.24M estimate. This represents a 14.29% miss on EPS and a 34.09% miss on sales estimates, with a year-over-year decrease in sales by 15.29%.
March 18, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tango Therapeutics reported a larger than expected quarterly loss and a significant miss in sales estimates, indicating potential short-term negative impact on its stock price.
Missing both EPS and sales estimates significantly, especially with a year-over-year decrease in sales, typically leads to negative investor sentiment and could result in a short-term decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100